Funding
This work was supported by grants from the Arthritis Research UK
(17702), Medical Research Council (4050502589), Bupa Foundation,
National Institute for Health Research (NIHR) Southampton Biomedical
Research Centre, University of Southampton and University Hospital
Southampton NHS Foundation Trust, and NIHR Musculoskeletal Biomedical
Research Unit, University of Oxford. IS and AP were funded by the
Medical Research Council (MRC) (programme code U105960371). KMG is
supported by the UK Medical Research Council (MC_UU_12011/4), the
National Institute for Health Research (NIHR Senior Investigator
(NF-SI-0515-10042), NIHR Southampton 1000DaysPlus Global Nutrition
Research Group (17/63/154) and NIHR Southampton Biomedical Research
Centre (IS-BRC-1215-20004)), the European Union (Erasmus+ Programme
ImpENSA 598488-EPP-1-2018-1-DE-EPPKA2-CBHE-JP) and the British Heart
Foundation (RG/15/17/3174). The work leading to these results was
supported by the European Union’s Seventh Framework Programme
(FP7/2007-2013), projects EarlyNutrition and ODIN under grant agreements
numbers 289346 and 613977, and by the BBSRC (HDHL-Biomarkers,
BB/P028179/1), as part of the ALPHABET project, supported by an award
made through the ERA-Net on Biomarkers for Nutrition and Health (ERA
HDHL), Horizon 2020 grant agreement number 696295. We are extremely
grateful to Merck GmbH for the kind provision of the Vigantoletten
supplement. Merck GmbH had no role in the trial execution, data
collection, analysis or manuscript preparation.